Management of Fatty Liver Disease and Obesity

Risk Stratification and Lifestyle Interventions

The American Association for the Study of Liver Diseases recommends lifestyle modification with a target weight loss of 7-10% as the cornerstone of treatment for all patients with fatty liver disease and obesity, as this degree of weight loss improves steatohepatitis and can reverse fibrosis in nearly half of patients 1, 2, 3
The European Association for the Study of the Liver suggests calculating the FIB-4 score to stratify patients: scores <1.3 indicate low risk, 1.3-2.67 indicate intermediate risk, and >2.67 indicate high risk of advanced fibrosis 2
Liver stiffness measurement by transient elastography provides additional stratification: <8.0 kPa indicates low risk, 8.0-12.0 kPa indicates intermediate risk, and >12.0 kPa indicates high risk 2
Patients with intermediate or high-risk scores require hepatology referral for specialized management and consideration of liver biopsy 4, 2
Patients with F2 or greater fibrosis are at significantly increased risk of liver-related complications and mortality, making them candidates for pharmacologic therapy in addition to lifestyle changes 1, 3

Aim for 7-10% weight loss to achieve improvement in steatohepatitis and fibrosis, though even 5% weight loss improves hepatic steatosis 1, 2, 3
Weight loss of ≥10% achieves fibrosis improvement in 45% of patients, making this the optimal target for those with advanced disease 1, 3
Adopt a Mediterranean diet pattern featuring daily consumption of vegetables, fruits, fiber-rich cereals, nuts, fish or white meat, and olive oil 2, 5
Implement a hypocaloric diet with 500-1000 kcal deficit per day to achieve the target weight loss of 500-1000g per week 2
Limit simple sugars, red meat, processed meats, and ultra-processed foods, as carbohydrate intake is associated with metabolic syndrome and severity of intrahepatic inflammation 1, 2
Perform at least 150-300 minutes of moderate-intensity exercise per week or 75-150 minutes of vigorous-intensity exercise 2, 5
Vigorous exercise (≥6 METs) is required for fibrosis improvement, though moderate exercise reduces hepatic fat independent of weight loss 1, 3

Statins are safe and strongly recommended for managing dyslipidemia in fatty liver disease patients and should not be withheld due to hepatotoxicity concerns 2, 3, 5
GLP-1 receptor agonists (liraglutide, semaglutide) are preferred for patients with type 2 diabetes and fatty liver disease, as they have demonstrated NASH resolution in 39% vs 9% placebo in biopsy-proven NASH 4, 3
Pioglitazone improves steatohepatitis in patients with NASH, with RCT-proven efficacy on liver histology 4
Pharmacologic treatment aimed at liver disease should be limited to patients with biopsy-proven NASH and fibrosis ≥F2, as this stage is an independent predictor of liver-related complications 1, 3, 5

Annual follow-up with repeated non-invasive tests including FIB-4 and liver stiffness measurement is recommended for low-risk patients (FIB-4 <1.3 or LSM <8.0 kPa) 2, 5
More frequent monitoring every 6 months with liver function tests and non-invasive fibrosis markers is recommended for intermediate and high-risk patients 2, 5
Hepatocellular carcinoma surveillance every 6 months is required for patients with advanced fibrosis (F3) or cirrhosis (F4) 3, 5